


PHARMACEUTICAL 2021

Annovis Bio Inc. Rank 127 of 402







PHARMACEUTICAL 2021

Annovis Bio Inc. Rank 127 of 402



The relative strengths and weaknesses of Annovis Bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Annovis Bio Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 63% points. The greatest weakness of Annovis Bio Inc. is the variable Expenses, reducing the Economic Capital Ratio by 51% points.

The company's Economic Capital Ratio, given in the ranking table, is 173%, being 125% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	8,119
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	578
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	1,178
Other Revenues	0
Property and Equipment	0
Research and Development	3,054
Selling, General and Administrative Expense	3,586

Output Variable	Value in 1000 USD
Assets	8,119
Liabilities	578
Expenses	6,640
Revenues	0
Stockholders Equity	7,541
Net Income	-5,462
Comprehensive Net Income	-5,462
Economic Capital Ratio	173%

